Since its discovery in 1961, messenger ribonucleic acid (mRNA) has been researched extensively for potential application to treat a wide range of human diseases by exploiting natural in vivo protein synthesis machinery. For drug development to be successful, a range of obstacles associated with in vitro transcribed (IVT) mRNA, such as its short half-life and unfavourable immunogenicity must be overcome. In this short article, our expert Dr Jo-Anne Riley, Senior Scientist Oligonucleotide Services discusses the characterisation challenges for mRNA-based therapies.

Please complete the form to access the article